Answer
Burosumab binds to and inhibits fibroblast growth factor 23 (FGF23), increasing tubular phosphate reabsorption in the kidneys.
Sources for this answer
- Crysvita solution for subcutaneous injectionKyowa Kirin Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 13Document updated
Sources checked